At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Ombitasvir/ABT-450/Ritonavir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection
In Brief
A Phase 2 clinical trial evaluating Ombitasvir/ABT-450/Ritonavir, Dasabuvir, and 1 other intervention for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 46 participants.
Detailed Summary
To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV) ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive HCV genotype (GT) 1a-infected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionApr 2016
Study CompletionDec 2016
TodayJul 2026
First PostedJul 10, 2015
Enrollment StartJun 1, 2015
Primary CompletionApr 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.0 years ago
Interventions
Ombitasvir/ABT-450/Ritonavirdrug
Ombitasvir/ABT-450/ritonavir combination tablets
Dasabuvirdrug
Dasabuvir tablets
Ribavirin (RBV)drug
Ribavirin tablets